UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. - Wikidata - wikimedia - TriplyDB

UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.

UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.

http://www.wikidata.org/entity/Q46007462

about

Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial.Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues.Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).UGT1A1 polymorphisms in cancer: impact on irinotecan treatment.Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy.Selecting multimodal therapy for rhabdomyosarcoma.Pharmacotherapy for pediatric soft-tissue sarcomas.Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients.Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.

P2860

Q28068930-29ED3B0D-DEBD-4428-807D-BC2B7BB9A8CB Q33427471-F90FB00A-9F5A-489D-969F-96EFABE842D3 Q34059702-7495A655-E3A6-4732-B9DC-FF4B20195135 Q35050772-7822AD06-9FB0-4B0A-B0E1-AF6F60F4DF41 Q36171894-1FD4BC61-B07C-459A-8482-B09E3846E958 Q37567702-01E73754-076A-488A-8DF0-B031B7825269 Q37682812-D74023CD-8E96-4CAE-85FF-9BEE7FDA93D9 Q37712297-343BF5A1-4D28-4A16-80AC-E7C698C595A6 Q37726433-0D2014B5-2F41-4472-B4D9-847A3C2EF203 Q37782096-D81928DD-E7AD-47B5-9505-4ABEC358DE98 Q37838445-C922E948-67B6-4FC1-8729-340486A5309D Q37887337-1D6F729D-A931-4A4A-BFAD-E375E2D88444 Q39399754-81341726-D52D-4FF3-BC77-28A7A81C959F Q39566084-6CEA2261-CCA4-40C1-B55D-8A387CBF0AD4 Q52362144-192CA119-BBF0-47BB-867E-1CD3AC692222 Q53253992-464C4920-508B-4869-A77B-B231E9F0A705

P2860

UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.

http://www.wikidata.org/entity/Q46007462

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

UGT1A1*28 genotype predicts ga ...... intermediate-dose irinotecan.

@en

UGT1A1*28 genotype predicts ga ...... intermediate-dose irinotecan.

@nl

type

label

UGT1A1*28 genotype predicts ga ...... intermediate-dose irinotecan.

@en

UGT1A1*28 genotype predicts ga ...... intermediate-dose irinotecan.

@nl

prefLabel

UGT1A1*28 genotype predicts ga ...... intermediate-dose irinotecan.

@en

UGT1A1*28 genotype predicts ga ...... intermediate-dose irinotecan.

@nl

P1433

Q46007462-16877C52-D923-4547-90C9-5D0A70A0E0D3

P1476

Q46007462-2F0C175C-E511-418A-95CC-3CB5EF5AFFC1

P2093

Q46007462-54793964-AA5F-4B79-B453-2BC7698D1760

Q46007462-A552EEE2-EF2A-49B3-8A8E-A92CB401E3AE

Q46007462-B24F6F11-A9C9-43BA-89FF-201065E8D1C7

Q46007462-C6A183CA-369A-4F0F-BA6E-E712571742F2

Q46007462-CBFA654C-EBBB-4727-B6EE-F5D0176BD768

Q46007462-D5AA03F3-783D-4868-B012-25DE5A4D14FA

Q46007462-DE17BFB2-C531-496A-8FBB-FA17DAFE03E9

P2860

Q46007462-0132666E-1B53-48E8-95FD-2528EEEB71B8

Q46007462-14F53D40-A39E-4245-961B-C36C7B9AD2F2

Q46007462-17246218-F5D8-4AF2-8689-B1ACF91F28C3

Q46007462-191B524A-F7BE-43B9-A7FC-A49BE4B1B6EA

Q46007462-33026BC3-5DDC-401B-80D6-6B11A1735B3F

Q46007462-43C3E677-E98F-49AD-9030-B1B6D437B24C

Q46007462-5120969E-6B06-4D26-8514-A935B06E48C4

Q46007462-5371E21D-4EFD-4070-BA34-29E669ED5E83

Q46007462-80A530AA-4070-42BD-BC0D-F507AB9B2007

Q46007462-8738F366-1F6A-4175-AF0A-519899E8110D

P304

Q46007462-F87D7B02-C32B-4413-BF4C-0E95E4532B73

P31

Q46007462-2B2EF884-C103-44C1-9632-BD83A2F20624

P356

Q46007462-A6AF14F7-B5CA-4D82-B702-111A42C8D927

P433

Q46007462-2185E4BA-52D0-4884-B913-0003D2BD2817

P478

Q46007462-F47C3780-F9ED-4DAF-B647-94684BFCBF85

P50

Q46007462-23406477-253C-4B7A-9CB2-98494B461CD0

Q46007462-55A59CEA-9001-4752-A595-B36EB73EA091

Q46007462-87581AB6-B084-4941-BE47-EE20C332E791

Q46007462-D4B80656-349F-4C1F-A885-2D0730655FCF

P577

Q46007462-046497A4-C3BF-4B43-81FB-1C57078184EE

P698

Q46007462-79BE40F4-FF90-4B57-8488-1B16CEC71CB1

P356

P1433

Pharmacogenomics

P1476

UGT1A1*28 genotype predicts ga ...... intermediate-dose irinotecan.

@en

P2093

Gregory Wilson

http://www.w3.org/2001/XMLSchema#string

Kristen D Hadfield

http://www.w3.org/2001/XMLSchema#string

Laura J Minchell

http://www.w3.org/2001/XMLSchema#string

Mark Saunders

http://www.w3.org/2001/XMLSchema#string

Roberta Ferraldeschi

http://www.w3.org/2001/XMLSchema#string

Saifee Mullamitha

http://www.w3.org/2001/XMLSchema#string

Simon Tobi

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome.

UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.

Clinical and pharmacogenetic factors associated with irinotecan toxicity.

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.

Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.

P304

733-739

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.09.20

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Fiona Blackhall

William G. Newman

Stephen A. Roberts

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19450125

http://www.w3.org/2001/XMLSchema#string